{
  "compound": "THC, cannabinoids",
  "condition": "TOURETTE_SYNDROME",
  "effect_size": "N/A (guideline)",
  "study_type": "CLINICAL_GUIDELINE",
  "source": "NORML:TS_GUIDELINE_001",
  "participants": "Evidence-based guideline",
  "year": 2011,
  "notes": "European Guidelines for Tourette Syndrome: Cannabis Section",
  "confidence": "medium",
  "abstract": "THC recommended as third-line treatment for adults with treatment-resistant TS; Evidence level B; Benefits outweigh risks in refractory cases"
}